Issue link: https://viewer.e-digitaledition.com/i/1481285
At Penn State Health, Breakthrough Nuclear Medicine Treatment for Advanced Prostate Cancer BY THOMAS CROCKER PATIENTS WITH META STATIC castra- tion-resistant prostate cancer (mCRPC) often fail conventional treatments, includ- ing surgery, radiation therapy, hormone therapy, chemotherapy and previously limited nuclea r medicine treatment options. In March, the FDA approved a new nuclear medicine treatment that uses radiopharmaceutical Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which tar- gets prostate-specific membrane antigen (PSMA) on prostate cancer cells and was shown to give some patients additional months of improved quality of life. 1 "Pluvicto is introduced at the end of a chain of therapeutic options," says Mark Tulchinsky, MD, FACNM, FSNMMI, associate director of nuclear medicine at Penn State Health Milton S. Hershey Med ica l Cent er a nd a profes sor of radiolog y and medicine at Penn State College of Medicine. "It becomes another barrier to stopping cancer from growing and spreading. In many cases, Pluvicto decreases the volume of metastatic pros- tate cancer in the body. If not for this new therapy, these patients might experience unfortunate complications caused by a growing tumor, such as suffering from pain and disabilities." In July, following more than a year of preparation by Dr. Tulchinsky and a multidisciplinary group of colleagues at the Genitourinary Tumor Board co-led by Monika Joshi, MD, MRCP, the Penn State Cancer Institute became one of the first three centers in Pennsylvania to start administering Pluvicto. Because of the high demand for this treatment across the country and the limited supply, no more centers in Pennsylvania will administer Pluvicto for now. Dr. Tu lchinsk y is g ratef u l for the team's dedicated efforts that brought this life-prolonging therapy to the Penn State Cancer Institute. This teamwork cou ld not have succeeded w ithout a strong support of Radiology leadership, including Timothy J. Mosher, MD, chair of Radiology, and Thomas W. Allen, MD, chief of Nuclear Medicine. RESULTS OF THE VISION TRIAL Pluvicto is a theranostic treatment — one that combines the strengths of diagnostic techniques with those of therapeutic nuclear medicine. The FDA designated it as a breakthrough drug for acceler- ated approval. The approvals were based on the phase 3 VISION trial results published in The New England Journal of Medicine. The trial included 831 patients with mCRPC who had previously received androgen receptor pat hway in hibitor t herapy and ta xane-based chemotherapy. The research also demonstrated the PSMA target on the tumor using the Locametz scan. Researchers followed the partici- pants for a median of 20.9 months. All patients were continued on a stan- dard of care treatment, while two-thirds were randomly selected to also receive Pluvicto. 1 Compared with patients who received standard of care alone, patients who received Pluvicto demonstrated a signif icantly better imaging-based progression-free survival (8.7 months versus 3.4 months) and overall survival (15.3 months versus 11.3 months). 1 "For me, the most encouraging finding from the VISION tria l was how often Pluvicto was able to deter this aggres- sive and already advanced tumor from continuous growth or even clear it from a patient's body," Dr. Tulchinsky says. "More than ha lf of patients receiving Pluvicto either cleared cancer completely or shrunk it. None of the patients receiving only the standard of care showed tumor clearance, while only 3% showed some tumor shrinkage." Dr. Tulchinsky says Pluvicto can extend life by severa l months while keeping patients more functional, which is most uplifting for patients. He recalls patients' excitement when they learned about the Pluvicto outpatient therapy and shared their plans to spend more time with loved ones and pursue activities they enjoy. PATIENT SELECTION USING THERANOSTICS To select patients who may benefit from Pluvicto, clinicians use Locametz scans that can show whether patients' tumors are PSMA-positive. The diagnostic agent Locametz is aimed at the same target as the treatment agent Pluvicto. The use of imaging agents aimed at the PSMA target, such as Locametz, is a logical approach to identifying patients who may benefit from Pluvicto. This approach, known as theranostics, is poised to advance nuclear medicine therapies to achieve more significant results in prostate cancer and other malignancies. "Fusing diagnostic and therapeutic capabilities into a theranostic approach enables us first to see whether a patient has the targets we're looking for, and then send the therapeutic agent after those targets that we can see on the diagnostic image," Dr. Tulchinsky says. "We then have much greater assurance that the Pluv icto therapy w i ll be successf u l. Mark Tulchinsky, MD, FACNM, FSNMMI, associate director of nuclear medicine at Penn State Health Milton S. Hershey Medical Center, speaks with a patient during administration of Pluvicto. NOW AVAIL ABLE AT PENN STATE CANCER INSTITUTE, THE NOVEL R ADIOPHARMACEUTICAL PLUVICTO IS HELPING PATIENTS WITH ME TA STATIC CA STR ATION-RESISTANT PROSTATE CANCER LIVE LONGER WITH A BE T TER SENSE OF WELL-BEING. M D N E W S . C O M /// M D N E W S M I D - P E N N ■ 2 0 2 2 C O V E R F E A T U R E ❰❰❰❰❰ 0 5

